r960-9c7154027fd3807382a6cb8e890ef978.jpg


CEO says drugmaker will meet with advocates to explain company's plans and review the community's concerns. (AP Photo/Sue Ogrocki, File)

A high-priced drug approved last week to treat a rare disease that affects young boys is not hitting the market after criticism over its $89,000-a-year price tag.

Marathon Pharmaceuticals said Monday that it is delaying the launch of Emflaza, a drug to treat the rare muscular disorder Duchenne muscular dystrophy. The Illinois drugmaker didn’t say how long the drug would be delayed or when it initially planned to hit the market.

The company’s CEO, Jeff Aronin, said in a letter that it is pausing the launch to meet with drug advocates and “explain our commercialization plans, review their concerns, discuss all options, and move forward with commercialization.”

The delay announced Monday comes the same day that Sen. Bernie Sanders, I-Vt., and Rep. Elijah Cummings, D-Md., demanded answers about the $89,000 annual price for Emflaza.

The drug is a steroid that has been marketed overseas for $1,000. The Food and Drug Administration approved the drug to treat Duchenne’s muscular dystrophy last week.

Trump 'evaluating the situation' with national security adviser Mike Flynn

Top Story

President Trump is “evaluating the situation” regarding national security adviser Michael Flynn role in the administration, the White House said Monday.

“The president is evaluating the situation,” White House press secretary Sean Spicer. “He is speaking to vice president relative to the conversation the VP had with General Flynn and also speaking to various other people about what he considers he single most important subject there is – our national security.”

Spicer’s statement came approximately one hour after Kellyanne Conway said on TV that Flynn has “the full confidence of the president.

02/13/17 5:17 PM

Subscribe to Alerts

Learn more about Washington Examiner’s Alerts

Loading Next Article



Source link

About the Author:

Leave a Reply